In brief: Avantogen, Novogen, Peplin, ResMed
Friday, 02 September, 2005
Alastair Hood has resigned as a director of Avantogen (ASX:ACU), formerly Australian Cancer Technology, citing increased corporate and travel commitments with his investment company Bluespire as the reason for his departure.
Dr Graham Kelly has resigned as a director of Novogen (ASX:NRT) to focus on the development and expansion of its US subsidiary companies Glycotex and Marshall Edwards.
Former Queensland premier Wayne Goss will retire as a non-executive director of Peplin (ASX:PEP) at the company's annual general meeting. He was appointed as Deloitte Touche Tohmatsu's national chairman in June and is retiring as a Peplin director due to increased work commitments.
ResMed (ASX:RMD) has appointed US-based MediaFLO's CEO and president Richard Sulpizio as a director, replacing Christopher Bartlett, Professor Emertius of business administration at Harvard Business School.
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
